The goal of this laboratory is to generate a clinical grade source for cell-replacement based therapies for neurodegenerative diseases like Parkinson's, Amyotrophic Lateral Sclerosis and Multiple Sclerosis. They are developing strategies for the induction of specific neural phenotypes from human embryonic stem cells (HESCs) and their subsequent isolation. The lab is currently studying unique ligand/receptor targets, identified from gene expression profiles of adult and fetal human CNS derived cells, in their efficacy to drive HESCs towards the desired neural phenotype. The transplantation potential of the cells, thus generated, is extensively studied in appropriate animal models.
Windrem, M.S., Schanz, S., Guo, M., Tian, G., Washco, V., Stanwood, N., Rasband, M., Roy, N.S., Medergaard, N., Havton, L.A., Wang, S. and Goldman, S.A. (2008). Neonatal chimerization with human glial progenitor cells can both remyelinate and rescue the otherwise lethally hypomyelinated shiverer mouse. Cell Stem Cell. 2008 Jun 5; 2(6): 553-65.
Sim, F.J., Lang, J.K., Ali, T.A., Roy, N.S., Vates, G.E., Pilcher, W.H., Goldman, S.A. (2008). Statin treatment of adult human glial progenitors induces PPARgamma-mediated oligodendrocytic differentiation. Glia. 56:954-62.
Sim, F.J., Keyoung, H.M., Goldman, J.E., Kim, D.K., Jung, H.W., Roy, N.S., Goldman, S.A. (2006). Neurocytoma is a Tumor of Adult Neuronal Progenitor Cells. J Neurosci. 26: 12544-555.